Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

ESC 2015: ‘Shocking’ Outcomes Of Sleep Apnea-Heart Failure Trial Spell Gloom For ResMed

Executive Summary

Results from the SERVE-HF trial, presented at the recent European Society of Cardiology meeting and published in the NEJM, showed systolic heart failure patients with central sleep apnea treated with adaptive servo-ventilation actually had worse mortality outcomes than the control group. These results "shocked " both the respiratory and cardiology community and spell gloom for ResMed's sleep apnea therapy.



Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Add a personalized Question to your Analyst